Overview
Description
CSL Limited is a leading Australian multinational biotechnology company specializing in the research, development, manufacturing, and marketing of lifesaving medicines and vaccines. The company’s portfolio includes plasma-derived therapies for conditions such as hemophilia and immune deficiencies, influenza vaccines, and treatments for rare and serious diseases. CSL operates globally through its core divisions—CSL Behring, CSL Seqirus, and CSL Vifor—serving patients in over 100 countries. With a history dating back to 1916, CSL has played a pivotal role in advancing public health, including during major global health events like the COVID-19 pandemic. The company is listed on the CHI-X Market Australia – Limit Venue, providing investors access to one of the largest and most innovative biotech firms in the Asia-Pacific region. CSL’s commitment to scientific innovation and global health continues to shape the biotechnology sector and drive advancements in patient care.
About
CEO
Dr. Paul F. McKenzie Ph.D.
Employees
29904
Address
655 Elizabeth Street
Melbourne, 3000, VIC
Australia
Melbourne, 3000, VIC
Australia
Phone
61 3 9389 1911
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Australia
MIC code
XASX